Should local therapy for invasive breast cancer be customized on the basis of subtype?

被引：3

作者：

Caudle A.S. ^{[1
]}

Tereffe W. ^{[2
]}

Mittendorf E.A. ^{[1
]}

机构：

[1] Department of Surgical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX 77030

[2] Department of Radiation Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX 77030

来源：

Current Breast Cancer Reports | 2013年 / 5卷 / 2期

关键词：

Biological subtype; Breast cancer; Breast conservation; HER2; Hormone receptor; Ipsilateral breast tumor recurrence; Local-regional recurrence; Mastectomy; Post-mastectomy radiation;

D O I：

10.1007/s12609-013-0103-2

中图分类号：

学科分类号：

摘要：

Microarray analyses have identified intrinsic breast cancer subtypes with distinct gene expression profiles. These subtypes can be approximated by immunohistochemical analysis of markers routinely available in pathology reports, in particular hormone receptors (HR) and HER2. These approximated subtypes can be used to stratify patients with regard to long-term recurrence-free and breast cancer-specific survival, and local-regional recurrence (LRR)-free survival. Patients who are HR-/HER2- have the highest risk of LRR; however, there are no data supporting more aggressive local-regional treatment with surgery or radiation to reduce that risk for this group. It is possible that local-regional therapy could be limited for patients with more favorable subtypes (HR+/HER2-); however, more data are needed to support this strategy. © 2013 Springer Science+Business Media New York.

引用

页码：145 / 151

页数：6

共 31 条

[1]

Perou C., Sorlie T., Eisen M., Et al., Molecular portraits of human breast tumours, Nature, 406, pp. 747-752, (2000)

[2]

Sorlie T., Perou C., Tibshirani R., Et al., Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proc Natl Acad Sci U S A, 98, pp. 10869-10874, (2001)

[3]

Sorlie T., Tibshirani R., Parker J., Et al., Repeated observation of breast tumor subtypes in independent gene expression data sets, Proc Natl Acad Sci U S A, 100, pp. 8418-8423, (2003)

[4]

Sotiriou C., Neo S., McShane L., Et al., Breast cancer classification and prognosis based on gene expression profiles from a population-based study, Proc Natl Acad Sci U S A, 100, pp. 10393-10398, (2003)

[5]

Parker J., Mullins M., Cheang M., Et al., Supervised risk predictor of breast cancer based on intrinsic subtypes, J Clin Oncol, 27, pp. 1160-1167, (2009)

[6]

Rouzier R., Perou C., Symmans W., Et al., Breast cancer molecular subtypes respond differently to preoperative chemotherapy, Clin Cancer Res, 11, pp. 5678-5685, (2005)

[7]

Carey L., Perou C., Livasy C., Et al., Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study, JAMA, 295, pp. 2492-2502, (2006)

[8]

Cozick J., Dowsett M., Pineda S., Et al., Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer, J Clin Oncol, 29, pp. 4273-4278, (2011)

[9]

Dawood S., Hu R., Homes M., Et al., Defining breast cancer prognosis based on molecular phenotypes: Results from a large cohort study, Breast Cancer Res Treat, 126, pp. 185-192, (2011)

[10]

Mittendorf E.A., Buchholz T.A., Tucker S.L., Et al., Impact of chemotherapy sequencing on local-regional failure risk in breast cancer patients undergoing breast-conserving therapy, Ann Surg, 257, pp. 173-179, (2013)

← 1 2 3 4 →